Cingulate (CING) Competitors $4.48 +0.38 (+9.27%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CING vs. TRIB, WVFC, MURA, IOBT, VHAQ, THTX, OKUR, AADI, STTK, and KZRShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Trinity Biotech (TRIB), WVS Financial (WVFC), Mural Oncology (MURA), IO Biotech (IOBT), Viveon Health Acquisition (VHAQ), Theratechnologies (THTX), OnKure Therapeutics (OKUR), Aadi Bioscience (AADI), Shattuck Labs (STTK), and Kezar Life Sciences (KZR). Cingulate vs. Trinity Biotech WVS Financial Mural Oncology IO Biotech Viveon Health Acquisition Theratechnologies OnKure Therapeutics Aadi Bioscience Shattuck Labs Kezar Life Sciences Trinity Biotech (NASDAQ:TRIB) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Do analysts prefer TRIB or CING? Cingulate has a consensus target price of $8.00, indicating a potential upside of 78.57%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cingulate 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is TRIB or CING more profitable? Cingulate has a net margin of 0.00% compared to Trinity Biotech's net margin of -34.39%. Trinity Biotech's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-34.39% N/A -21.37% Cingulate N/A -570.20%-236.15% Does the MarketBeat Community favor TRIB or CING? Trinity Biotech received 328 more outperform votes than Cingulate when rated by MarketBeat users. Likewise, 72.04% of users gave Trinity Biotech an outperform vote while only 70.00% of users gave Cingulate an outperform vote. CompanyUnderperformOutperformTrinity BiotechOutperform Votes33572.04% Underperform Votes13027.96% CingulateOutperform Votes770.00% Underperform Votes330.00% Does the media favor TRIB or CING? In the previous week, Trinity Biotech had 3 more articles in the media than Cingulate. MarketBeat recorded 9 mentions for Trinity Biotech and 6 mentions for Cingulate. Trinity Biotech's average media sentiment score of 0.73 beat Cingulate's score of 0.61 indicating that Trinity Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, TRIB or CING? Cingulate has lower revenue, but higher earnings than Trinity Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$56.83M0.17-$24.02M-$2.26-0.58CingulateN/AN/A-$23.53MN/AN/A Do institutionals & insiders have more ownership in TRIB or CING? 79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 17.1% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, TRIB or CING? Trinity Biotech has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500. SummaryTrinity Biotech beats Cingulate on 9 of the 15 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.39M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E RatioN/A10.57134.3717.77Price / SalesN/A243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book-0.065.474.674.68Net Income-$23.53M$153.61M$119.07M$226.08M7 Day Performance6.16%-2.00%-1.83%-1.04%1 Month Performance-8.94%-7.47%-3.62%1.04%1 Year Performance-32.33%31.80%31.63%26.28% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.6398 of 5 stars$4.48+9.3%$8.00+78.6%-34.5%$14.39MN/A0.0013Analyst UpgradeGap UpTRIBTrinity Biotech1.8036 of 5 stars$1.30-1.5%N/A-33.5%$10.06M$56.83M0.00480Gap DownWVFCWVS FinancialN/A$12.85flatN/A+4.9%$24.34M$16.11M13.8220MURAMural Oncology3.191 of 5 stars$3.37flat$16.00+374.8%N/A$57.36MN/A0.00119Analyst RevisionIOBTIO Biotech3.3072 of 5 stars$0.82-5.7%$9.33+1,038.2%-16.3%$57.32MN/A0.0030VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$56.56MN/A0.002High Trading VolumeTHTXTheratechnologiesN/A$1.22+1.7%N/A-10.3%$55.18M$81.76M0.00140Positive NewsOKUROnKure Therapeutics2.6095 of 5 stars$16.00-2.4%$37.50+134.4%N/A$54.79MN/A0.00N/AAADIAadi Bioscience1.1929 of 5 stars$2.22+0.5%$1.67-24.9%-53.3%$54.72M$25.07M-0.9740STTKShattuck Labs2.8175 of 5 stars$1.11-2.6%$8.67+680.8%-50.7%$54.42M$1.66M0.00100Analyst RevisionKZRKezar Life Sciences4.3591 of 5 stars$7.49+1.5%$40.50+440.7%-15.4%$53.85M$7M0.0060Analyst Revision Related Companies and Tools Related Companies Trinity Biotech Competitors WVS Financial Competitors Mural Oncology Competitors IO Biotech Competitors Viveon Health Acquisition Competitors Theratechnologies Competitors OnKure Therapeutics Competitors Aadi Bioscience Competitors Shattuck Labs Competitors Kezar Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CING) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CING Stock Alerts